Xinhua News Agency, April 21, China Resources Pharmaceutical Co., Ltd., Xinhua Pharmaceutical Co., Ltd., Hendi Pharmaceutical Co., Ltd., Yiling Pharmaceutical Co., Ltd., Shanghai Kaibao, Zhongsheng Pharmaceutical Co., Ltd. According to the news, on April 21, the National Bureau of Disease Control and Prevention said that due to the XBB.1.16 epidemic in some Asian countries, the proportion of COVID-19 XBB.1.16 in recent imported cases in China has increased.